Robust
The same process；High successful cultivation rate＞95%
Competent
Billion level cells；Specific T cells>60%
Affordable
Feeder cells-free；Non-viral vector at a low cost
Accessible
Less intensive pretreatment；IL-2 injection-free
Technological platforms
-
DeepTIL?cell expansion platform
-
Highly efficient TIL enrichment for all tumor types
Clinical-grade TILs can be obtained with a high successful rate ＞90%
-
Simplified process without feeder cells
The expansion of TILs becomes easier and cheaper with no healthy human PBMCs.
-
No lymphodepletion pre-treatment or IL-2 injections
Patients can receive treatment just in general wards.
-
-
NovaGMP? gene modification platform
-
Safer
No risk of wild-type virus mutaions.
-
Cheaper
The non-viral vector-based gene modification costs less than 1/10 of the viral vectors system.
-
More efficient
TILs have stronger anti-tumor activity and in vivo adaptation capability with transfection efficiency ＞45%.
-